Background: For patients (pts) with stage II-III triple negative breast cancer (TNBC), KEYNOTE-522 regimen, combining pembrolizumab with neoadjuvant chemotherapy (NACT), represented the current standard of care. Circadian rhythms regulate immune function, and retrospective studies have associated earlier administration of immune checkpoint inhibitors (ICIs) with improved outcomes. In early TNBC, data are limited, and recent evidence suggests that the effect of infusion timing may depend on baseline stromal tumour-infiltrating lymphocytes (sTILs).Aims: In this context, the present study aims to evaluate whether pembrolizumab infusion timing and baseline sTILs are associated with pathological complete response (pCR), and whether sTILs modulate the association between infusion timing and pCR.Methods: This retrospective single-centre study included pts with stage II–III TNBC treated with the KEYNOTE-522 regimen at Vall d’Hebron Institute of Oncology (2022-2026). The infusion time rate (ITR), defined as the proportion of the first four pembrolizumab infusions administered at or before the cohort median time of infusion, was analysed categorically (Early-dominant, ITR ≥50%, vs Late-dominant) and continuously. Associations with pCR were assessed using logistic regression models, univariate and adjusted for age, stage, Ki67 with additional adjustment for sTILs in models assessing association between timing and pCR.. Statistical interaction between infusion timing and sTILs was assessed.Results: This study included 90 pts and 52 achieved a pCR (57.8%). Median time of pembrolizumab infusion was 13:14. pCR rates were 52.7% in Early-dominant and 65.7% in Late-dominant pts (p=0.276). Higher sTILs were associated with higher odds of pCR at univariate (OR 1.31 by 5-percentage-point increase, 95% CI 1.15–1.54; p < 0.001), and adjusted analysis (aOR 1.29, 95% CI 1.13–1.52; p < 0.001). At multivariate analysis higher Ki67 expression was also associated with higher probability of pCR (aOR 1.42, 95% CI 1.15-1.80; p= 0.002). Infusion timing was not associated with pCR, either categorically (aOR 2.51, 95% CI 0.81–8.70; p = 0.124) or continuously (aOR 0.75, 95% CI 0.45–1.18; p = 0.224), whereas sTILs and Ki67 were significant. No significant interaction between timing and sTILs was observed (categorical: adjusted interaction OR 0.79, 95% CI 0.57–1.11; p = 0.149; continuous: 1.08, 95% CI 0.95–1.22; p = 0.233).Conclusions: Pembrolizumab infusion timing was not associated with pCR, and sTILs did not modify this association. Response to neoadjuvant chemo-immunotherapy was mainly associated with of sTILs.
Background: For patients (pts) with stage II-III triple negative breast cancer (TNBC), KEYNOTE-522 regimen, combining pembrolizumab with neoadjuvant chemotherapy (NACT), represented the current standard of care. Circadian rhythms regulate immune function, and retrospective studies have associated earlier administration of immune checkpoint inhibitors (ICIs) with improved outcomes. In early TNBC, data are limited, and recent evidence suggests that the effect of infusion timing may depend on baseline stromal tumour-infiltrating lymphocytes (sTILs).Aims: In this context, the present study aims to evaluate whether pembrolizumab infusion timing and baseline sTILs are associated with pathological complete response (pCR), and whether sTILs modulate the association between infusion timing and pCR.Methods: This retrospective single-centre study included pts with stage II–III TNBC treated with the KEYNOTE-522 regimen at Vall d’Hebron Institute of Oncology (2022-2026). The infusion time rate (ITR), defined as the proportion of the first four pembrolizumab infusions administered at or before the cohort median time of infusion, was analysed categorically (Early-dominant, ITR ≥50%, vs Late-dominant) and continuously. Associations with pCR were assessed using logistic regression models, univariate and adjusted for age, stage, Ki67 with additional adjustment for sTILs in models assessing association between timing and pCR.. Statistical interaction between infusion timing and sTILs was assessed.Results: This study included 90 pts and 52 achieved a pCR (57.8%). Median time of pembrolizumab infusion was 13:14. pCR rates were 52.7% in Early-dominant and 65.7% in Late-dominant pts (p=0.276). Higher sTILs were associated with higher odds of pCR at univariate (OR 1.31 by 5-percentage-point increase, 95% CI 1.15–1.54; p < 0.001), and adjusted analysis (aOR 1.29, 95% CI 1.13–1.52; p < 0.001). At multivariate analysis higher Ki67 expression was also associated with higher probability of pCR (aOR 1.42, 95% CI 1.15-1.80; p= 0.002). Infusion timing was not associated with pCR, either categorically (aOR 2.51, 95% CI 0.81–8.70; p = 0.124) or continuously (aOR 0.75, 95% CI 0.45–1.18; p = 0.224), whereas sTILs and Ki67 were significant. No significant interaction between timing and sTILs was observed (categorical: adjusted interaction OR 0.79, 95% CI 0.57–1.11; p = 0.149; continuous: 1.08, 95% CI 0.95–1.22; p = 0.233).Conclusions: Pembrolizumab infusion timing was not associated with pCR, and sTILs did not modify this association. Response to neoadjuvant chemo-immunotherapy was mainly associated with of sTILs.
Impact of timing of neoadjuvant pembrolizumab infusion on pathological response in patients treated with the KEYNOTE-522 regimen: a single-centre retrospective study.
BONOMI, GIORGIO
2024/2025
Abstract
Background: For patients (pts) with stage II-III triple negative breast cancer (TNBC), KEYNOTE-522 regimen, combining pembrolizumab with neoadjuvant chemotherapy (NACT), represented the current standard of care. Circadian rhythms regulate immune function, and retrospective studies have associated earlier administration of immune checkpoint inhibitors (ICIs) with improved outcomes. In early TNBC, data are limited, and recent evidence suggests that the effect of infusion timing may depend on baseline stromal tumour-infiltrating lymphocytes (sTILs).Aims: In this context, the present study aims to evaluate whether pembrolizumab infusion timing and baseline sTILs are associated with pathological complete response (pCR), and whether sTILs modulate the association between infusion timing and pCR.Methods: This retrospective single-centre study included pts with stage II–III TNBC treated with the KEYNOTE-522 regimen at Vall d’Hebron Institute of Oncology (2022-2026). The infusion time rate (ITR), defined as the proportion of the first four pembrolizumab infusions administered at or before the cohort median time of infusion, was analysed categorically (Early-dominant, ITR ≥50%, vs Late-dominant) and continuously. Associations with pCR were assessed using logistic regression models, univariate and adjusted for age, stage, Ki67 with additional adjustment for sTILs in models assessing association between timing and pCR.. Statistical interaction between infusion timing and sTILs was assessed.Results: This study included 90 pts and 52 achieved a pCR (57.8%). Median time of pembrolizumab infusion was 13:14. pCR rates were 52.7% in Early-dominant and 65.7% in Late-dominant pts (p=0.276). Higher sTILs were associated with higher odds of pCR at univariate (OR 1.31 by 5-percentage-point increase, 95% CI 1.15–1.54; p < 0.001), and adjusted analysis (aOR 1.29, 95% CI 1.13–1.52; p < 0.001). At multivariate analysis higher Ki67 expression was also associated with higher probability of pCR (aOR 1.42, 95% CI 1.15-1.80; p= 0.002). Infusion timing was not associated with pCR, either categorically (aOR 2.51, 95% CI 0.81–8.70; p = 0.124) or continuously (aOR 0.75, 95% CI 0.45–1.18; p = 0.224), whereas sTILs and Ki67 were significant. No significant interaction between timing and sTILs was observed (categorical: adjusted interaction OR 0.79, 95% CI 0.57–1.11; p = 0.149; continuous: 1.08, 95% CI 0.95–1.22; p = 0.233).Conclusions: Pembrolizumab infusion timing was not associated with pCR, and sTILs did not modify this association. Response to neoadjuvant chemo-immunotherapy was mainly associated with of sTILs.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bonomi_Giorgio.pdf
Accesso riservato
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119669